CRISPR/Cas及其衍生编辑技术在基因治疗中的应用进展

doi:10.19586/j.2095-2341.2020.0144

生物技术进展 ›› 2021, Vol. 11 ›› Issue (4): 518-525.DOI: 10.19586/j.2095-2341.2020.0144

CRISPR/Cas及其衍生编辑技术在基因治疗中的应用进展

权春菊(), 郑忠亮()

武汉大学生命科学学院，武汉 430027

收稿日期:2020-11-06 接受日期:2021-03-04 出版日期:2021-07-25 发布日期:2021-08-02
通讯作者: 郑忠亮
作者简介:权春菊 E-mail：1096150987@qq.com；
基金资助:
国家自然科学基金项目(81372441)

Application Progress of CRISPR/Cas and its Derivative Editing Technology in Gene Therapy

Chunju QUAN(), Zhongliang ZHENG()

College of Life Sciences，Wuhan University，Wuhan 430027，China

Received:2020-11-06 Accepted:2021-03-04 Online:2021-07-25 Published:2021-08-02
Contact: Zhongliang ZHENG

摘要/Abstract

摘要：

基因治疗是指利用基因编辑技术对细胞基因进行“修饰”而达到治疗的目的。CRISPR/Cas的出现为基因编辑提供了简单、高效和多功能的平台，同时，为克服DNA双链断裂产生的不良影响，基于CRISPR/Cas的新型技术，如碱基编辑器（base editors，BE）、Prime Editors（PE）和Cas13效应器，被相继开发出来。目前，CRISPR/Cas及其衍生编辑技术已被广泛应用于动物细胞模型构建、药物靶点筛查和基因功能研究等领域，在基因治疗领域也展现出广阔的应用前景。基于此，简要介绍了CRISPR/Cas及其衍生编辑技术，综述了其在单基因遗传病、肿瘤和其他疾病的基因治疗中的应用进展，并分析了其当下面临的挑战，以期为基因编辑在单基因遗传病、肿瘤和其他疾病治疗领域提供理论参考。

关键词: CRISPR/Cas, 碱基编辑器, Prime Editors, Cas13效应器, 基因治疗

Abstract:

Gene therapy refers to the use of gene editing technology to “modify” cell genes to achieve the purpose of treatment. The emergence of CRISPR/Cas provides a simple， efficient and multifunctional platform for gene editing. Meanwhile， in order to overcome the adverse effects caused by DNA double?strand breaks， new technologies based on CRISPR/Cas， such as base editors （BE）， Prime Editors （PE） and Cas13 effector， have been developed one after another. At present， CRISPR/Cas and its derivative editing technologies have been widely used in animal cell model construction， drug target screening and gene function research， and also show broad application prospects in the field of gene therapy. Based on this， CRISPR/Cas and its derivative editing technology were briefly introduced， and their application progress in gene therapy of single gene genetic diseases， tumors and other diseases was summarized. And the challenges they faced at present were analyzed， in order to provide relevant theoretical reference for gene editing in the treatment of single?gene genetic diseases， tumors and other diseases.

Key words: CRISPR/Cas, base editors, Prime Editors, Cas13 effector, gene therapy

中图分类号:

Q789

权春菊, 郑忠亮. CRISPR/Cas及其衍生编辑技术在基因治疗中的应用进展[J]. 生物技术进展, 2021, 11(4): 518-525.

Chunju QUAN, Zhongliang ZHENG. Application Progress of CRISPR/Cas and its Derivative Editing Technology in Gene Therapy[J]. Current Biotechnology, 2021, 11(4): 518-525.

图/表 1

参考文献 61

1	DOUDNA J A. The promise and challenge of therapeutic genome editing[J]. Nature, 2020, 578(7794): 229-236.
2	TAMAS L, YANG D, WALDMAN A S. Repair of a specific double-strand break generated within a mammalian chromosome by yeast endonuclease I-SceI [J]. Nucl. Acids Res., 1994, 22(25): 5649-5657.
3	WYMAN C, KANAAR R. DNA double-strand break repair: all's well that ends well [J]. Annu. Rev. Genet., 2006, 40(1):363-383.
4	URNOV F D, REBAR E J, HOLMES M C, et al.. Genome editing with engineered zinc finger nucleases[J]. Nat. Rev. Genet., 2010, 11(9): 636-646.
5	JOUNG J K, SANDER J D. TALENs: a widely applicable technology for targeted genome editing [J]. Nat. Rev. Mol. Cell Biol., 2012, 14(1): 49-55.
6	CHO S W, KIM S, KIM J M, et al.. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease [J]. Nat. Biotechnol., 2013, 31(3): 230-232.
7	CONG L, RAN F A, COX D M, et al.. Multiplex genome engineering using CRISPR/Cas systems [J]. Science, 2013, 339(6121): 819-823.
8	MALI P, YANG L H, ESVELT K M, et al.. RNA-guided human genome engineering via Cas9 [J]. Science, 2013, 339(6121): 823-826.
9	MAKAROVA K S, WOLF Y I, ALKHNBASHI O S, et al.. An updated evolutionary classification of CRISPR-Cas systems [J]. Nat. Rev. Microbiol., 2015, 13(11): 722-736.
10	MOHANRAJU P, MAKAROVA K S, ZETSCHE B, et al.. Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems [J/OL]. Science, 2016, 353(6299): aad5147[2021-06-04]. . DOI: 10.1126/science.aad5147 .
11	ZEBALLOS C M A, GAJ T. Next-generation CRISPR technologies and their applications in gene and cell therapy [J/OL]. Trends Biotechnol., 2020, 1: S0167-7799(20)30287-0[2021-06-04]. .
12	WANG F, WANG L, ZOU X, et al.. Advances in CRISPR-Cas systems for RNA targeting, tracking and editing[J]. Biotechnol. Adv., 2019, 37(5): 708-729.
13	任云晓, 肖茹丹, 娄晓敏, 等. 基因编辑技术及其在基因治疗中的应用[J]. 遗传, 2019, 41(1): 18-27.
14	JINEK M, CHYLINSKI K, FONFARA I, et al.. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity [J]. Science, 2012, 337(6096): 816-821.
15	KOMOR A C, KIM Y B, PACKER M S, et al.. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage [J]. Nature, 2016, 533(7603): 420-424.
16	NISHIDA K, ARAZOE T, YACHIE N, et al.. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems [J/OL]. Science, 2016, 353(6305): aaf8729[2021-06-04]. . DOI: 10.1126/science.aaf8729 .
17	GAUDELLI N M, KOMOR A C, REES H A, et al.. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage [J]. Nature, 2017, 551(7681): 464-471.
18	ANZALONE A V, RANDOLPH P B, DAVIS J R, et al.. Search-and-replace genome editing without double-strand breaks or donor DNA [J]. Nature, 2019, 576(7785): 149-157.
19	YEH W H, CHIANG H, REES H A, et al.. In vivo base editing of post-mitotic sensory cells [J/OL]. Nat. Commun., 2018, 9(1): 2184[2021-06-04]. .
20	VILLIGER L, GRISCH-CHAN H M, LINDSAY H, et al.. Treatment of a metabolic liver disease by in vivo genome base editing in adult mice [J]. Nat. Med., 2018, 24(10): 1519-1525.
21	LEVY J M, YEH W H, PENDSE N, et al.. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses [J]. Nat. Biomed. Eng., 2020, 4(1): 97-110.
22	LIM C K W, GAPINSKE M, BROOKS A K, et al.. Treatment of a mouse model of ALS by in vivo base editing [J]. Mol. Ther., 2020, 28(4): 1177-1189.
23	WINTER J, LUU A, GAPINSKE M, et al.. Targeted exon skipping with AAV-mediated split adenine base editors [J/OL]. Cell Discov., 2019, 5:41[2021-06-04]. .
24	ABUDAYYEH O O, GOOTENBERG J S, ESSLETZBICHLER P, et al.. RNA targeting with CRISPR-Cas13 [J]. Nature, 2017, 550(7675): 280-284.
25	ABUDAYYEH O O, GOOTENBERG J S, KONERMANN S, et al.. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector [J/OL]. Science, 2016, 353(6299): aaf5573[2021-06-04]. . DOI: 10.1126/science.aaf5573 .
26	EAST-SELETSKY A, O'CONNELL M R, KNIGHT S C, et al.. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection [J]. Nature, 2016, 538(7624): 270-273.
27	MEESKE A J, NAKANDAKARI-HIGA S, MARRAFFINI L A. Cas13-induced cellular dormancy prevents the rise of CRISPR-resistant bacteriophage [J]. Nature, 2019, 570(7760): 241-245.
28	SMARGON A A, COX D B T, PYZOCHA N K, et al.. Cas13b is a type VI-B CRISPR-associated RNA-guided RNase differentially regulated by accessory proteins Csx27 and Csx28 [J]. Mol. Cell, 2017, 65(4):618-630.
29	PARK S H, LEE C M, DEVER D P, et al.. Highly efficient editing of the beta-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease [J]. Nucleic Acids Res., 2019, 47(15): 7955-7972.
30	KALKAN B M, KALA E Y, YUCE M, et al.. Development of gene editing strategies for human beta-globin (HBB) gene mutations [J/OL]. Gene, 2020, 734:144398[2021-06-04]. .
31	DEVER D P, BAK R O, REINISCH A, et al.. CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells [J]. Nature, 2016, 539(7629): 384-389.
32	KOSICKI M, TOMBERG K, BRADLEY A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements [J]. Nat. Biotechnol., 2018, 36(8): 765-771.
33	RYU S M, KOO T, KIM K, et al.. Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy [J]. Nat. Biotechnol., 2018, 36(6): 536-539.
34	REN J, ZHAO Y. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9 [J]. Protein Cell, 2017, 8(9): 634-643.
35	ZHAO J, LIN Q, SONG Y, et al.. Universal CARs, cellsuniversal T, and universal CAR T cells [J/OL]. J. Hematol. Oncol., 2018, 11(1): 132[2021-06-04]. .
36	LU Y, XUE J, DENG T, et al.. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer [J]. Nat. Med., 2020, 26(5): 732-740.
37	LIU D, ZHAO X, TANG A, et al.. CRISPR screen in mechanism and target discovery for cancer immunotherapy [J/OL]. Biochim. Biophys. Acta Rev. Cancer, 2020, 1874(1): 188378[2021-06-04]. .
38	CYRANOSKI D. Chinese scientists to pioneer first human CRISPR trial [J]. Nature, 2016, 535(7613): 476-477.
39	CYRANOSKI D. CRISPR gene-editing tested in a person for the first time [J]. Nature, 2016, 539(7630): 479.
40	STADTMAUER E A, FRAIETTA J A, DAVIS M M, et al.. CRISPR-engineered T cells in patients with refractory cancer [J/OL]. Science, 2020, 367(6481):eaba7365[2021-06-04]. . DOI: 10.1126/science.aba7365 .
41	ZAFRA M P, SCHATOFF E M, KATTI A, et al.. Optimized base editors enable efficient editing in cells, organoids and mice [J]. Nat. Biotechnol., 2018, 36(9): 888-893.
42	ZHAO X, LIU L, LANG J, et al.. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment [J]. Cancer Lett., 2018, 431:171-181.
43	WANG E, ZHOU H, NADORP B, et al.. Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation [J]. Cell Stem Cell, 2021, 28(4):718-731.
44	ZHU W, XIE K, XU Y, et al.. CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse [J]. Virus Res., 2016, 217:125-132.
45	ROSSIDIS A C, STRATIGIS J D, CHADWICK A C, et al.. In utero CRISPR-mediated therapeutic editing of metabolic genes [J]. Nat. Med., 2018, 24(10): 1513-1518.
46	ZHANG X, ZHAO W, NGUYEN G N, et al.. Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing [J/OL]. Sci. Adv., 2020, 6(34):eabc2315[2021-06-04]. . DOI: 10.1126/sciadv.abc2315 .
47	CHADWICK A C, WANG X, MUSUNURU K. In vivo base editing of PCSK9 (proprotein convertase subtilisin/kexin type 9) as a therapeutic alternative to genome editing [J]. Arterioscler. Thromb. Vasc. Biol., 2017, 37(9): 1741-1747.
48	ZHOU H, SU J, HU X, et al.. Glia-to-neuron conversion by CRISPR-CasRx alleviates symptoms of neurological disease in mice [J]. Cell, 2020, 181(3): 590-603.
49	KOBLAN L W, DOMAN J L, WILSON C, et al.. Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction [J]. Nat. Biotechnol., 2018, 36(9): 843-846.
50	LIANG P, XIE X, ZHI S, et al.. Genome-wide profiling of adenine base editor specificity by EndoV-seq [J/OL]. Nat. Commun., 2019, 10(1): 67[2021-06-04]. .
51	REES H A, KOMOR A C, YEH W H, et al.. Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery [J/OL]. Nat. Commun., 2017, 8(1):15790[2021-06-04]. .
52	GRüNEWALD J, ZHOU R, GARCIA S P, et al.. Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors [J]. Nature, 2019, 569(7756): 433-437.
53	JIANG W, FENG S, HUANG S, et al.. BE-PLUS: a new base editing tool with broadened editing window and enhanced fidelity [J]. Cell Res., 2018, 28(8): 855-861.
54	GAUDELLI N M, LAM D K, REES H A, et al.. Directed evolution of adenine base editors with increased activity and therapeutic application [J]. Nat. Biotechnol., 2020, 38(7): 892-900.
55	ZHANG X, CHEN L, ZHU B, et al.. Increasing the efficiency and targeting range of cytidine base editors through fusion of a single-stranded DNA-binding protein domain [J]. Nat. Cell Biol., 2020, 22(6): 740-750.
56	JVAN HAASTEREN, LI J, SCHEIDELER O J, et al.. The delivery challenge: fulfilling the promise of therapeutic genome editing [J]. Nat. Biotechnol., 2020, 38(7): 845-855.
57	MENDELL J R, AL-ZAIDY S, SHELL R, et al.. Single-dose gene-replacement therapy for spinal muscular atrophy [J]. N. Engl. J. Med., 2017, 377(18): 1713-1722.
58	Goldschmidt D, Scutti S. FDA approves gene therapy for a type of blindness[EB/OL]. (2017-12-21) [2021-06-29]. .
59	ALANIS-LOBATO G, ZOHREN J, MCCARTHY A, et al.. Frequent loss-of-heterozygosity in CRISPR-Cas9-edited early human embryos [J/OL]. Proc. Natl. Acad. Sci. USA, 2021, 118(22): e2004832117 [2021-06-04]. .
60	ZUCCARO M V, XU J, MITCHELL C, et al.. Reading frame restoration at the EYS locus, and allele-specific chromosome removal after Cas9 cleavage in human embryos [J]. Cell, 2020, 183(6):1650-1664.
61	CHARLESWORTH C T, DESHPANDE P S, DEVER D P, et al.. Identification of preexisting adaptive immunity to Cas9 proteins in humans [J]. Nat. Med., 2019, 25(2): 249-254.

[1]	于鲲, 薛佳琪, 王进宽, 余永涛. CRISPR/Cas9基因编辑技术在丝状真菌中的应用[J]. 生物技术进展, 2022, 12(5): 696-704.
[2]	高维崧, 窦金萍, 韦双, 刘兴健, 张志芳, 李轶女. CRISPR/Cas系统的分类及研究现状[J]. 生物技术进展, 2022, 12(4): 532-538.
[3]	费云燕, 杨军, 景德道, 林添资, 李闯, 钱华飞, 曾生元, 韩华新, 龚红兵. CRISPR/Cas技术在抗除草剂作物育种中的研究与应用进展[J]. 生物技术进展, 2022, 12(2): 189-197.
[4]	李书翔, 安丽萍, 梁德娟, 王凯旋, 赵建国. 朊病毒病治疗方法的研究进展[J]. 生物技术进展, 2022, 12(2): 229-235.
[5]	曹巧, 史占良, 张国丛, 班进福, 郑树松, 傅晓艺, 张士昌, 何明琦, 韩然, 高振贤. CRISPR/Cas9技术在小麦育种中的应用进展[J]. 生物技术进展, 2021, 11(6): 661-667.
[6]	谢宇宙, 付伟, 闫超杰, 王智, 朱鹏宇, 任永超, 张永江, 相宁. 基于CRISPR/Cas原理的转基因产品检测技术研究进展[J]. 生物技术进展, 2021, 11(4): 430-437.
[7]	曹豪豪,张红兵,薛溪发,李左群,闫洪波,李会宣. 新型基因编辑技术在单细胞微藻中的应用进展[J]. 生物技术进展, 2021, 11(1): 9-15.
[8]	杜梦潭,刘兴健,胡小元,张志芳,李轶女. 腺相关病毒的生产方式及其在基因治疗中的应用[J]. 生物技术进展, 2019, 9(4): 326-331.
[9]	郑红艳,王磊. CRISPR/Cas基因编辑技术及其在作物育种中的应用[J]. 生物技术进展, 2018, 8(3): 185-190.
[10]	吕宝北,赵鹏翔,张鑫,马雪梅,谢飞. CRISPR/Cas9在肿瘤治疗中的研究进展[J]. 生物技术进展, 2018, 8(3): 191-196.
[11]	王友华,邹婉侬,康宇立,唐巧玲,孙国庆. CRISPR/Cas系统研发进展及展望[J]. 生物技术进展, 2017, 7(6): 594-600.
[12]	汪超甲,王辉,胡钧涛,胡胜利,张宇强,成于思,雷尚国. CRISPR/Cas9敲除pyk2基因对人脑胶质瘤细胞增殖、迁移及侵袭能力的影响[J]. 生物技术进展, 2017, 7(4): 338-344.
[13]	赵丽琴,席斌,彭华松. 腺相关病毒(AAV)载体研究进展[J]. 生物技术进展, 2012, 2(2): 110-115.

CRISPR/Cas及其衍生编辑技术在基因治疗中的应用进展

Application Progress of CRISPR/Cas and its Derivative Editing Technology in Gene Therapy

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 61

相关文章 13

编辑推荐

Metrics

本文评价